Top 15 women in pharma; Pay-for-delay deals face another setback;

> Who are the top 15 women in pharma? Our sister publication FiercePharma has unveiled their picks, and there's quite a few interesting names in the bunch. List

> Congress is one step closer to enacting a ban on deals paying generic drug makers to hold off on launching products competing with the big brands. A Senate panel voted yesterday to ban branded drugmakers from engaging in this practice, known as "pay for delay." FiercePharma

> Famed investor George Soros has taken a 7.1 percent stage in revenue cycle management vendor Emdeon. With the need for that industry climbing, seems he could have done worse. FierceHealthFinance

> By making some tweaks to how it used its core business intelligence system, Mount Sinai Medical Center managed to reclaim $3 million in missed charges within one year. Pretty cool, huh?  FierceHealthFinance

And Finally... If you're a customer at a bordello, one would think the only green they'd care about is the color of your money...but not here. Article

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.